Back to results
US 8,802,697 B2Granted
Inhibitors of the fibroblast growth factor receptor
AssigneeBlueprint Medicines Corporation
InventorsNeil Bifulco, Jr., Natasja Brooijmans, Brian L. Hodous, Joseph L. Kim, Chandrasekhar V. Miduturu
Life of this patent
Estimating the term…
Abstract
Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
Claims9
A compound of Formula 1, or pharmaceutically acceptable salt thereof:
- wherein
- ring A is a 3-8 membered aryl, heteroaryl, heterocyclic or alicyclic group;
- X is CH or N;
- Y is CH or N—R4 where R4 is H or C1-6 alkyl;
- L is —[C(R5)(R6)]q—, where each of R5 and R6 is, independently, H or C1-6 alkyl, wherein q is 0-4;
- each of R1 and R3 is independently, halo, cyano, optionally substituted C1-6 alkoxy, hydroxy, oxo, amino, amido, alkyl urea, optionally substituted C1-6 alkyl, or optionally substituted C1-6 heterocyclyl;
- two R2 are halo and two R2 are C1-6 alkoxy;
- m is 0-3;
- n is 4;
- p is 0-2;
- and
- Warhead is selected from the group consisting of
- wherein X is halo or triflate;
- and
- each of Ra, Rb, and Rc is independently, H, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 cycloalkyl, or cyano.
12 more elements
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.